Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 10, Issue 1, 2000, Pages 1-6

  Hernandez Mijares A ^a,c   Lluch, I ^a   Vizcarra, E ^b   Martinez Triguero M L ^a   Ascaso, J F ^b,c   Carmena, R ^b,c  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Ciprofibrate; Diabetic dyslipidemia; Insulin receptors; Type 2 diabetes mellitus

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; CIPROFIBRATE; CLOFIBRIC ACID; DRUG DERIVATIVE; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTERIOSCLEROSIS; ARTICLE; BLOOD; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; AREA UNDER CURVE; ARTERIOSCLEROSIS; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLOFIBRIC ACID; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID METABOLISM; LIPOPROTEIN(A); MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 0034137070     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Diabetes Drafting Group (1985) Prevalence of small vessel disease in diabetic patients from 14 centers: the World Health Organization multinational study of vascular disease in diabetics. Diabetologia 28: 615-640
2. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L (1989) Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabetic men: a general population study. Br Med J 299: 1127-1131
3. Wilson PWF, Kannel WB, Anderson KM (1985) Lipids, glucose intolerance and vascular disease: the Framingham study. Monogr Atheroscler 13: 1-11
4. Carmena R, Ascaso JF, Serrano S, Martinez-Valls J, Soriano P (1985) Serum HDL concentration in patients with type 1 and type 2 diabetes mellitus. Monogr Atheroscler 13: 115-120
5. Howard BV (1996) Lipoprotein metabolism in diabetes. Curr Opin Lipidol 5: 212-220
6. Consensus Statement Detection and Management of Lipid Disorders in Diabetes (1996) Diabetes Care 19: S96-S102
7. Barasch E, Berderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Pelled B, Reisin L, Roguin N, Goldbourt U (1995) Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The bezafibrate infarction Prevention Study Group. J Clin Epidemiol 48: 757-765
8. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KGMM (1990) Lowering of plasma glucose concentration with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13: 855-863
9. Berderly M, Graff E, Reicher-Reiss H, Behar S, Brunner DF, Goldbourt U (1996) Fibrinogen is a predictor of mortality in coronary heart disease patients. The bezafibrate Infarction Prevention Study Group. Arterioscler Thromb Vasc Biol 16: 351-356
10. International Taskforce for the Prevention of Coronary Heart Disease: Prevention of Coronary Heart Disease. Scientific Background and New Clinical Guidelines (1992) Nutr Metab Cardiovasc Dis 2: 113-156
11. Trinder P (1969) Enzymatic method for glucose determination. Ann Clin Biochem 6: 24-27
12. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC (1979) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475
13. Ter FH, Baarscheer T, Folet JWT (1984) Influence of free glycerol on enzymatic measurement of triglycerides. Clin Chem 30: 1102-1103
14. Havel RJ, Eder HJ, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1354
15. 2+/dextrane sulphate in its enzymatic measurement. Clin Chem 24: 931-933
16. Maciejko JJ, Levinson SS, Markyyech L, Smith MP, Blevins RD (1987) New assay of apoliprotein A-I and B rate nephelometry evaluated. Clin Chem 33: 2065-2069
17. Labeur C, Michiels G, Burg J, Usher DC, Rosenew M (1989) Lipoprotein (a) quantified by an enzyme-linked immunosorbent assay with monoclonal antibodies. Clin Chem 35: 1380-1384
18. Clauss A (1957) Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 17: 237-242
19. Nathan D, Raskin P (1984) A convenient automated method for high performance liquid chromatography measurement of glycated (glycosilated) hemoglobin. Clin Chem 30: 813-814
20. Soeldner JS, Slone D (1965) Critical variables in the radioimmnunoassay of serum insulin using the double antibody technic. Diabetes 14: 771-779
21. Gambhir K, Archer J, Bradley C (1978) Characteristics of human erythrocyte insulin receptors. Diabetes 27: 701-708
22. Scatchard G (1949) The attraction of protein for small molecules and ions. Ann NY Acad Sci 51: 660-672
23. Statgraphics Plus 1.4.1995. Statistical Graphic Corp.
24. Arnold A, McAuliff JP, Power LG, Phillips DK, Beyler AL (1979) The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug. Atherosclerosis 32: 155-163
25. Olsson AG, Orö L (1982) Dose-response study of the effect of ciprofibrate on serum lipoprotein concentration in hyperlipoproteinaemia. Atherosclerosis 42: 229-243
26. Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE (1982) Ciprofibrate in the therapy of type II hypercholesterolemia: a double blind trial. Atherosclerosis 44: 211-221
27. Rouffy J, Chanu B, Bakir F, Dijan F, Goy-Loeper J (1985) Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apolipoproteins A and B. Atherosclerosis 54: 273-281
28. Cattin L, Da-Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D, Mannarino E, Ventura A (1992) Efficacy of ciprofibrate in primary hyperlipidemia. Curr Ther Res 51: 750-562
29. Oro L, Carlson LA, Olsson A, Poole PH (1992) Long term efficacy and safety of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res 51: 750-562
30. Betteridge DJ (1993) Ciprofibrate: a profile. Postgrad Med J 69: S42-S47
31. Bruckert E, Dejager S, Chapman MJ (1993) Ciprofibrate therapy normalises the atherogenic low-density subspecies profile in combined hyperlipidemia. Atherosclerosis 100: 91-102
32. Shen DC, Fuh MMT, Shieh SM, Chen YDI, Raven GM (1991) Effect of genfibrozil treatment in sulfonylurea-treated patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 73: 503-510
33. Vinik AI, Colwell JA (1993) Effects of gemfibrozil on triglycerides levels in patients with NIDDM. Diabetes Care 16: 37-44
34. Dean JD, Durrington PN (1996) Treatment of dyslipoproteinemia in diabetes mellitus. Diabetic Med 13: 297-312
35. Taskinen MR (1991) Why and how treated hyperlipidemia in diabetic patients. Nutr Metab Cardiovasc Dis 1: 201-206
36. Ernst E, Resh KL (1993) Fibrinogen as a cardiovascular risk factor: a meta analysis and review of the literature. Ann Intern Med 118: 956-963
37. Niort G, Cassader M, Gambino R, Pagano G (1992) Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidemic type 2 diabetic patients. Diabetes Metab 18: 221-228.
38. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B deFaire U (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet 347: 849-853
39. Vinik AI, Colwell JA (1993) Effects of gemfibrozil on triglycerides levels in patients with NIDDM. Diabetes Care 16: 37-44
40. Ricardi G, Genovese S, Saldamacchia G, Patti L, Marotta G, Postiglione A, Rivellese A, Capaldo B, Mancini M (1989) Effects of bezafibrate on insulin secretion and peripherical insulin sensitiv in hyperlipemic patients with and without diabetes. Atherosclerosis 75: 175-181
41. Janes IR, Swai A, Taylor R, Miller M, Laker F, Alberti KG (1990) Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13: 855-863
42. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto M, Nambu S, Baba S (1988) Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 11: 495-499
43. Ip C, Tepperman J (1976) Effect of p-chlorophenoxyisobutyrate on the antilipolytic action of insulin and insulin binding in isolated adipocytes. J Lipid Res 17: 68-73
44. Kelly CM, Fantus G (1995) Insulin binding in non-insulin-dependent Diabetes Mellitus is correlated with glycemic control: clinical evidence for abnormal receptor regulation in NIDDM. Metabolism 44: 506-512